HIV Highlights-ART - HIV - Clinical Care Options

Highlights of Atlanta 2013: ART as Treatment and Prevention

Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, comment on the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Faculty: Joel E. Gallant MD, MPH, Kathleen E. Squires MD, Andrew R. Zolopa MD

Released: 5/7/2013
Highlights of Atlanta 2013: ART as Treatment and Prevention

Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, highlight the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/21/2013
Dolutegravir-Based Regimens Associated With Similar Efficacy and Safety Across Treatment-Naive Patient Subgroups in Phase III SPRING-2, SINGLE Trials

Few differences reported from subset analyses of 2 phase III trials including efficacy and discontinuation rates of dolutegravir-based regimens compared with efavirenz- and raltegravir-based regimens

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/13/2013
OPTIONS: NRTI-Omitting Regimen Noninferior to NRTI-Including Regimen in Patients With 3-Class Antiretroviral Experience and/or Treatment Failure Starting New Optimized Regimen

Randomized noninferiority study in patients with PI, NNRTI, and NRTI experience and/or viral resistance suggests that NRTIs may be safely omitted from a new optimized regimen without compromising efficacy.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/12/2013
Investigational NNRTI MK-1439 Demonstrates Encouraging Safety, Antiviral Activity in Treatment-Naive HIV-Infected Patients in Early-Phase Study

Both doses of MK-1439 monotherapy tested in the study produced similar > 1 log10 decreases in HIV-1 RNA over 7 days.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/12/2013
Efficacy and Safety of Novel Oral CCR5/CCR2 Receptor Antagonist Cenicriviroc Plus Tenofovir DF/Emtricitabine Compared With Tenofovir DF/Emtricitabine/Efavirenz in Treatment-Naive Patients

In treatment-naive patients with CCR5-tropic HIV infection, combination of cenicriviroc plus tenofovir DF/emtricitabine associated with generally similar virologic responses at Week 24 compared with efavirenz plus tenofovir DF/emtricitabine, with fewer discontinuations due to adverse events.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
SAILING: Dolutegravir Superior to Raltegravir at Week 24 in Treatment-Experienced, Integrase Inhibitor–Naive Patients

In interim analysis, lower rates of virologic failure and integrase inhibitor resistance in dolutegravir-treated patients vs those receiving raltegravir, with similar safety profile.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
SECOND-LINE: Lopinavir/Ritonavir Plus Raltegravir Noninferior to Lopinavir/Ritonavir Plus NRTIs in Patients Failing First-line ART

Study results validate WHO-recommended second-line therapy of boosted PI plus NRTIs and lend support to a potential new second-line strategy using NRTI-sparing raltegravir-based regimen.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/10/2013
Frequency of Transmitted HIV Resistance Among ARV-Naive HIV-Infected Patients Stable in HOPS During 1999-2011

More than one third of patients in cohort did not have genotypic resistance tests before antiretroviral therapy in most recent period.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/8/2013
Tenofovir Alafenamide Demonstrates Comparable Efficacy, Improved Renal and Bone Safety Profiles vs Tenofovir DF When Each Coformulated With Elvitegravir/Cobicistat/Emtricitabine in Treatment-Naive Patients

Similar high rates of virologic suppression through Week 24 in each arm, but serum creatinine increases and BMD decreases were smaller in the tenofovir alafenamide arm than in the tenofovir DF arm.

Source: 2013 Conference on Retroviruses and Opportunistic Infections

Date Posted: 3/8/2013

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Other Sites

Topics

Educational Formats

Program Resources

User Resources

PDF
Video

Help
Site Tour
RSS

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

HIV Highlights-ART Source: 2013 Conference on Retroviruses and Opportunistic Infections*
Conference Program HIV Highlights-ART • Capsule Summaries (14) • Downloadable slideset • CCO Slideset (CME) HIV Highlights-Comorbidity, Coinfection • Capsule Summaries (15) • Downloadable slideset • CCO Slideset (CME)	Latest Content 10 of 16 Shown Highlights of Atlanta 2013: ART as Treatment and Prevention Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, comment on the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting. Source: 2013 Conference on Retroviruses and Opportunistic Infections Faculty: Joel E. Gallant MD, MPH, Kathleen E. Squires MD, Andrew R. Zolopa MD Released: 5/7/2013 Highlights of Atlanta 2013: ART as Treatment and Prevention Joel E. Gallant, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, highlight the most clinically relevant reports on antiretroviral therapy as treatment and prevention from this important annual meeting. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/21/2013 Dolutegravir-Based Regimens Associated With Similar Efficacy and Safety Across Treatment-Naive Patient Subgroups in Phase III SPRING-2, SINGLE Trials Few differences reported from subset analyses of 2 phase III trials including efficacy and discontinuation rates of dolutegravir-based regimens compared with efavirenz- and raltegravir-based regimens Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/13/2013 OPTIONS: NRTI-Omitting Regimen Noninferior to NRTI-Including Regimen in Patients With 3-Class Antiretroviral Experience and/or Treatment Failure Starting New Optimized Regimen Randomized noninferiority study in patients with PI, NNRTI, and NRTI experience and/or viral resistance suggests that NRTIs may be safely omitted from a new optimized regimen without compromising efficacy. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/12/2013 Investigational NNRTI MK-1439 Demonstrates Encouraging Safety, Antiviral Activity in Treatment-Naive HIV-Infected Patients in Early-Phase Study Both doses of MK-1439 monotherapy tested in the study produced similar > 1 log10 decreases in HIV-1 RNA over 7 days. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/12/2013 Efficacy and Safety of Novel Oral CCR5/CCR2 Receptor Antagonist Cenicriviroc Plus Tenofovir DF/Emtricitabine Compared With Tenofovir DF/Emtricitabine/Efavirenz in Treatment-Naive Patients In treatment-naive patients with CCR5-tropic HIV infection, combination of cenicriviroc plus tenofovir DF/emtricitabine associated with generally similar virologic responses at Week 24 compared with efavirenz plus tenofovir DF/emtricitabine, with fewer discontinuations due to adverse events. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 SAILING: Dolutegravir Superior to Raltegravir at Week 24 in Treatment-Experienced, Integrase Inhibitor–Naive Patients In interim analysis, lower rates of virologic failure and integrase inhibitor resistance in dolutegravir-treated patients vs those receiving raltegravir, with similar safety profile. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 SECOND-LINE: Lopinavir/Ritonavir Plus Raltegravir Noninferior to Lopinavir/Ritonavir Plus NRTIs in Patients Failing First-line ART Study results validate WHO-recommended second-line therapy of boosted PI plus NRTIs and lend support to a potential new second-line strategy using NRTI-sparing raltegravir-based regimen. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/10/2013 Frequency of Transmitted HIV Resistance Among ARV-Naive HIV-Infected Patients Stable in HOPS During 1999-2011 More than one third of patients in cohort did not have genotypic resistance tests before antiretroviral therapy in most recent period. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/8/2013 Tenofovir Alafenamide Demonstrates Comparable Efficacy, Improved Renal and Bone Safety Profiles vs Tenofovir DF When Each Coformulated With Elvitegravir/Cobicistat/Emtricitabine in Treatment-Naive Patients Similar high rates of virologic suppression through Week 24 in each arm, but serum creatinine increases and BMD decreases were smaller in the tenofovir alafenamide arm than in the tenofovir DF arm. Source: 2013 Conference on Retroviruses and Opportunistic Infections Date Posted: 3/8/2013 10 of 16 Shown Show 6 More Loading...	Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC Contact Info Educational grants provided by: Educational grants support only the CME-certified components of this program.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Source: 2013 Conference on Retroviruses and Opportunistic Infections*

Conference Program

Latest Content